PMID- 34686406
OWN - NLM
STAT- MEDLINE
DCOM- 20220110
LR  - 20220110
IS  - 1873-460X (Electronic)
IS  - 1056-8727 (Linking)
VI  - 35
IP  - 12
DP  - 2021 Dec
TI  - Design and rationale of DISCOVER global registry in type 2 diabetes: Real-world 
      insights of treatment patterns and its relationship with cardiovascular, renal, 
      and metabolic multimorbidities.
PG  - 108077
LID - S1056-8727(21)00296-8 [pii]
LID - 10.1016/j.jdiacomp.2021.108077 [doi]
AB  - AIM: The DISCOVER Global Registry (DGR) aims to provide insights into patient 
      attributes and treatment patterns in patients with type 2 diabetes mellitus 
      (T2DM) seen in clinical practice and understand the patterns and impact of 
      treatment strategies on cardio-renal-metabolic multimorbidities. It aims to 
      augment the real-world evidence base created by the DISCOVER study. METHODS: The 
      ongoing study is a global, prospective, open-source, physician-led registry and 
      involves non-interventional data collection through cloud-based electronic case 
      report form platform from participants with T2DM receiving care as part of 
      routine clinical practice. The DGR will collect longitudinal prospective data on 
      the following: (a) patient, healthcare provider, and healthcare system 
      characteristics; (b) treatment patterns and factors influencing therapy changes; 
      (c) disease duration and glycemic control; (d) management of micro and/or 
      macrovascular complications; (e) management of associated risk factors; (f) 
      outcomes (hospitalization/death), (g) quality of care indicators (eye/foot 
      examination); (h) healthcare resource utilization; and (i) patient-reported 
      outcomes. CONCLUSION: Establishment of this long-term, scalable, and sustainable 
      global registry offers opportunities to enhance understanding of care gaps, 
      establish quality benchmarks, and understand the role of various treatment 
      strategies in addressing the multifactorial pathophysiology of T2DM and 
      associated comorbidities- potentially enabling transformation of clinical data 
      into actionable insights for improving patient outcomes.
CI  - Copyright (c) 2021. Published by Elsevier Inc.
FAU - Khunti, Kamlesh
AU  - Khunti K
AD  - University of Leicester, Leicester, UK. Electronic address: kk22@leicester.ac.uk.
FAU - Heerspink, Hiddo J L
AU  - Heerspink HJL
AD  - Department of Clinical Pharmacy and Pharmacology, University of Groningen, 
      University Medical Center, Groningen, the Netherlands. Electronic address: 
      h.j.lambers.heerspink@umcg.nl.
FAU - Lam, Carolyn S P
AU  - Lam CSP
AD  - National Heart Center Singapore and Duke-National University of Singapore Medical 
      School, Singapore; University Medical Center Groningen, Groningen, the 
      Netherlands. Electronic address: carolyn.lam@duke-nus.edu.sg.
FAU - Nicolucci, Antonio
AU  - Nicolucci A
AD  - Center for Outcomes Research and Clinical Epidemiology, Pescara, Italy. 
      Electronic address: nicolucci@coresearch.it.
FAU - Ramirez, Larisa
AU  - Ramirez L
AD  - AstraZeneca, Luton, UK. Electronic address: Larissa.Ramirez@astrazeneca.com.
FAU - Surmont, Filip
AU  - Surmont F
AD  - AstraZeneca, Cambridge, UK. Electronic address: Filip.Surmont@astrazeneca.com.
FAU - Fenici, Peter
AU  - Fenici P
AD  - AstraZeneca, Cambridge, UK. Electronic address: Peter.Fenici@astrazeneca.com.
FAU - Kosiborod, Mikhail
AU  - Kosiborod M
AD  - Saint Luke's Mid-America Heart Institute, Kansas City, MO, USA; University of 
      Missouri-Kansas City, MO, USA. Electronic address: mkosiborod@saint-lukes.org.
LA  - eng
GR  - DH_/Department of Health/United Kingdom
PT  - Journal Article
PT  - Multicenter Study
PT  - Observational Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20211013
PL  - United States
TA  - J Diabetes Complications
JT  - Journal of diabetes and its complications
JID - 9204583
SB  - IM
MH  - Cardiovascular Diseases/epidemiology
MH  - Cloud Computing
MH  - Comorbidity
MH  - Diabetes Mellitus, Type 2/complications/*epidemiology/therapy
MH  - Humans
MH  - Internationality
MH  - Internet
MH  - Kidney Diseases/epidemiology
MH  - Longitudinal Studies
MH  - Metabolic Diseases/epidemiology
MH  - Prospective Studies
MH  - *Registries/statistics & numerical data
MH  - Research Design
MH  - Risk Factors
OTO - NOTNLM
OT  - Diabetes global registry
OT  - Healthcare resource utilization
OT  - Prospective real-world data
OT  - Type 2 diabetes mellitus
OT  - micro and macrovascular complications
EDAT- 2021/10/24 06:00
MHDA- 2022/01/11 06:00
CRDT- 2021/10/23 05:34
PHST- 2021/09/06 00:00 [received]
PHST- 2021/10/07 00:00 [accepted]
PHST- 2021/10/24 06:00 [pubmed]
PHST- 2022/01/11 06:00 [medline]
PHST- 2021/10/23 05:34 [entrez]
AID - S1056-8727(21)00296-8 [pii]
AID - 10.1016/j.jdiacomp.2021.108077 [doi]
PST - ppublish
SO  - J Diabetes Complications. 2021 Dec;35(12):108077. doi: 
      10.1016/j.jdiacomp.2021.108077. Epub 2021 Oct 13.